Human B1 cells and uses thereof
US9371514B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2011 |
| Grant date | Jun 21, 2016 |
| Priority date | — |
| Expiry date | Sep 22, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70553
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b−. The present invention is also directed to a method of isolating human natural immunoglobulin-producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample that express surface biomarkers CD20, CD43 and CD27, and, optionally, CD11b. In addition, the present invention is directed to a methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient having a B1 cell disorder, and treating a patient having a B1 cell disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.